

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization
International Bureau



(43) International Publication Date
21 November 2002 (21.11.2002)

PCT

(10) International Publication Number
WO 02/091997 A2

(51) International Patent Classification⁷:

A61K

(81) Designated States (national): AF, AG, AI, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, IU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZM, ZW.

(21) International Application Number: PCT/US02/14642

(22) International Filing Date: 9 May 2002 (09.05.2002)

(25) Filing Language: English

(26) Publication Language: English

(84) Designated States (regional): ARIPO patent (GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

(30) Priority Data:
60/290,051 11 May 2001 (11.05.2001) US

(71) Applicant (for all designated States except US): PRO-VIRUS, INC. [US/US]; 930 Clopper Road, Gaithersburg, MD 20878 (US).

(72) Inventors; and

(75) Inventors/Applicants (for US only): GROENE, William, S. [US/US]; 5746 Windsong Court, New Market, MD 21774 (US). MILLER, Jeffrey, A. [US/US]; 316 Clearfield Drive, Lincoln University, PA 19352 (US). MUELLER, Stephen, N. [US/US]; 95 Ashley Court, Myersville, MD 21773 (US).

(74) Agent: KREISLER, Lewis, J.; Legal Department, 930 Clopper Road, Gaithersburg, MD 20878 (US).

Published:

— without international search report and to be republished upon receipt of that report

For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.



WO 02/091997 A2

(54) Title: ONCOLYTIC VIRUS THERAPY

(57) Abstract: A method of treating a human subject with cancer is disclosed. A pharmaceutical composition is administered to the subject, the pharmaceutical composition comprising human leukocytes and a replication-competent oncolytic virus in suspension in a physiologically acceptable solution. Alternatively the pharmaceutical composition comprises human leukocytes or platelets infected with an oncolytic virus.

ONCOLYTIC VIRUS THERAPY

5 BACKGROUND OF THE INVENTION

“Treatment of Neoplasms with Viruses” (WO 00/62735) relates to a method of administering viruses that are able to replicate and kill neoplastic cells with a deficiency in the IFN-mediated antiviral response. One specific aspect of this 10 patent involves the “systemic” administration of such viruses.

Paramyxoviruses are known to interact with erythrocytes and agglutinate them. They are reported to elute from erythrocytes with lower efficiency than influenza viruses. Howe, C. and Lee, L.T. (Adv. Virus Res. 17:1-50, 1972). Furthermore, 15 the specific inhibition of hemagglutination of erythrocytes caused by paramyxoviruses through neutralization by antibodies specific to viral coat proteins is a well understood phenomenon.

Schirmacher et al (Int. J of Oncology 16:363-373, 2000) have shown that NDV 20 will activate mouse macrophages for anti-tumor activity. The experimental results appearing below demonstrate that NDV does not preferentially bind to mouse leukocytes when added to mouse whole blood.

Bonina et al (Giorn. Batt. Virol. Immun., LXXVIII, 254-261, 1985) show that 25 human macrophages could support the growth of NDV.

Woodruff et al (Cellular Immunology 5:296-306, 1972) and Woodruff and Woodruff (J of Immunology 116(6):2176-2183, 1974) found that NDV agglutinates rat, mouse and human lymphocytes *in vitro*. 30

Faden et al (Blood, 58:221-7,1981) showed that NDV will bind to human neutrophils *in vitro*.

None of the above indicate any preferential binding of NDV to leukocytes over erythrocytes.

The literature describes the binding of NDV to red blood cells (usually chicken).

5 As NDV is not pathogenic in man it is a surprising result to find that NDV binds preferentially to the white blood cell component of human blood.

The literature indicates that the binding of NDV to cells occurs through the interaction of the Neuraminidase of the viral HN protein with sialic acid residues 10 attached to cell surface proteins. Human erythrocytes have a very high density of sialic acid residues attached to surface proteins. The ratio of erythrocytes to leukocytes in human blood is approximately 1000 to 1. Thus, it is especially surprising that NDV binds to the leukocyte fraction instead of the much more numerous erythrocytes.

15

SUMMARY OF THE INVENTION

This invention provides a method of treating a human subject with cancer, comprising administering to the subject an amount of a pharmaceutical 20 composition effective to treat the subject, the pharmaceutical composition comprising human leukocytes and a replication-competent oncolytic virus in suspension in a physiologically acceptable solution, wherein the virus binds specifically to the leukocytes; and the ratio of plaque-forming units of the virus to 25 number of leukocytes in the composition is at least 1:100, thereby treating the subject.

This invention provides a method of treating a human subject with cancer, comprising administering to the subject an amount of a pharmaceutical composition effective to treat the subject, the pharmaceutical composition 30 comprising human cells infected with an oncolytic virus in suspension in a physiologically acceptable solution, wherein the cells are leukocytes or platelets, thereby treating the subject.

This invention provides the use of a pharmaceutical composition to treat a human subject with cancer or in the manufacture of a medicament for the treatment of cancer, the pharmaceutical composition comprising: (a) human leukocytes and a replication-competent oncolytic virus in suspension in a physiologically acceptable solution, wherein the virus binds specifically to the leukocytes and the ratio of plaque forming units of the virus to number of leukocytes in the composition is at least 1:100; or (b) human cells infected with an oncolytic virus in suspension in a physiologically acceptable solution, wherein the cells are leukocytes or platelets. Uses (a) and (b) are linked in that practicing use (a) generally involves practicing use (b) since the replication-competent oncolytic virus will generally infect the leukocytes.

This invention is based, in part, on the finding that an oncolytic virus such as NDV binds to leukocytes and platelets. NDV binds leukocytes preferentially compared to erythrocytes. Tumors involve inflammatory processes. Therefore leukocytes to which an oncolytic virus is bound or which are infected with an oncolytic virus are a particularly effective means of delivering oncolytic viruses.

DETAILED DESCRIPTION OF THE INVENTION

20

As used herein the term "human cells" means cells isolated from a human, or cultured cells that have been derived from cells isolated from a human and/or whose nucleic acid component has been altered by, for example, immortalization, irradiation or recombinant means. "Human leukocytes" and "human platelets" are 25 human cells that are leukocytes and platelets, respectively. Except where otherwise specified or required by the context the terms "cells" or "human cells" refer to leukocytes and/or platelets.

As used herein the term "plaque-forming unit" (pfu) means one infectious virus 30 particle.

As used herein the term "multiplicity of infection" (MOI) means the number of infectious virus particles added per cell.

As used herein the term "clonal virus" means a virus derived from a single infectious virus particle and for which individual molecular clones have significant nucleic acid sequence homology. For example, the sequence homology is such that at least eight individual molecular clones from the 5 population of virions have a sequence homology greater than 95% over 300 contiguous nucleotides.

As used herein the term "leukocyte virus complex" (LVC) means the complex formed when an oncolytic virus is mixed with a leukocyte cell population and the 10 virus has become associated with the cells. The term includes both cells where the virus is bound to the outside of the cell and cells which are infected by the virus.

As used herein a virus is said to "bind(s) specifically" to a given cell if such virus 15 binds to such cell with a greater specificity than such virus binds to erythrocytes. The terms bind(s) specifically and specifically bind(s) are used interchangeably.

As used herein "NDV" is an abbreviation for Newcastle Disease Virus.

20 As used herein the term "replication-competent" virus refers to a virus that produces infectious progeny in cancer cells.

As used herein the transitional term "comprising" is open-ended. A claim utilizing this term can contain elements in addition to those recited in such claim.

25

In accordance with this invention the human cells can be derived from any source. They can be donated by someone other than the subject. However if feasible it is generally preferred to use cells donated by the subject, for safety reasons. Optionally cells isolated from the donor can first be grown in culture and the 30 cultured cells are also considered to be cells of the donor from which they were derived. Examples of cultured cells that can be utilized in accordance with this invention include immortalized human leukocyte cell lines. Suitable cell lines are publicly available from sources such as the American Type Culture Collection, for example U-937 (ATCC No. CRL-1593.2) and KG-1 (ATCC No. CCL-246).

The leukocytes utilized in accordance with this invention (e.g. monocytes, neutrophils and lymphocytes including tumor-infiltrating lymphocytes) can be active or inactive. Techniques for inactivating leukocytes include irradiation.

5

The cells utilized in accordance with this invention can be isolated (for example by leukopheresis in the case of leukocytes). However it is not necessary to isolate the cells and whole blood can be used instead, in which case the pharmaceutical composition comprises the oncolytic virus suspended in whole blood or whole 10 blood containing leukocytes and/or platelets infected with the virus. Optionally the leukocytes or platelets are first isolated from whole blood, mixed or infected with the virus and then added back to the other blood components.

In different embodiments of this invention the leukocytes are selected from 15 monocytes, neutrophils and lymphocytes. In a more specific embodiment of this invention the leukocytes are tumor-infiltrating lymphocytes (TILs). TILs may be prepared for example by the method described in Rabinowich, H., et al., (Cancer Res. 47: 173-7, 1987).

20. In accordance with this invention the oncolytic virus utilized can be of low (lentogenic), moderate (mesogenic) or high (velogenic) virulence. The level of virulence is determined in accordance with the Mean Death Time in Eggs (MDT) test. (Alexander, "Chapter 27: Newcastle Disease" in Laboratory Manual for the Isolation and Identification of Avian Pathogens, 3rd ed., Purchase, et al. eds. 25 (Kendall/Hunt, Iowa), page 117.) Viruses are classified by the MDT test as lentogenic (MDT>90 hours); mesogenic (MDT from 60-90 hours); and velogenic (MDT<60 hours).

In an embodiment of this invention the virus is a clonal virus.

30

Referring to the method or use in which the pharmaceutical composition utilized comprises leukocytes and oncolytic virus in suspension, in an embodiment of such method the ratio of plaque-forming units of the virus to number of leukocytes in the composition is at least 1:1. Generally it is preferred that the leukocytes be

saturated with active virus particles. In the case of NDV saturation is achieved at a 200:1 ratio of plaque-forming units of the virus to number of leukocytes.

Accordingly in an embodiment of this invention the virus is NDV and the ratio of plaque-forming units of the virus to number of leukocytes in the composition is

5 from about 1:1 to about 200:1, and preferably is about 200:1.

In the method or use described above in which the pharmaceutical composition utilized comprises cells infected with an oncolytic virus, in an embodiment of such method the infected cells are at least one-tenth of one percent (0.1%) of the

10 total number of leukocytes and platelets in the composition, more preferably at least thirty percent and most preferably about one hundred percent. The virus utilized can be replication incompetent although preferably it is replication competent.

15 In an embodiment of this invention the oncolytic virus is selected from the group consisting of a Newcastle Disease Virus (NDV), a Mumps Virus, a Measles Virus, a Vesicular Stomatitis Virus, a Para-influenza Virus, an Influenza Virus, an Adenovirus, a Herpes I Virus, a Vaccinia Virus, and a Reovirus. In a more specific embodiment a Newcastle Disease Virus strain of moderate virulence can
20 be utilized.

The skilled clinician can determine the optimal amount of the composition to be administered in each case. Typically when the cells are leukocytes the effective amount is a daily dosage of the composition containing from 6×10^6 to 6×10^{10}

25 leukocytes per square meter of patient surface area, for example about 6×10^7 leukocytes per square meter of patient surface area. When the cells are platelets the effective amount is typically a daily dosage of the composition containing from 10^9 to 10^{11} platelets per square meter of patient surface area, for example about 10^{11} platelets per square meter of patient surface area.

30

The daily dosage of the composition can be administered to the subject in multiple administrations in the course of a single twenty-four hour period in which a portion of the daily dosage is administered at each administration. More preferably the daily dosage is administered in a single administration. In an

embodiment of this invention the daily dosage of the composition is administered to the subject at a frequency of from one to seven times (i.e. on each of from one to seven days) in a one-week period.

- 5 In accordance with this invention, any conventional route of administration is suitable for administering the pharmaceutical composition. For example the composition can be administered intravenously, intratumorally, intraperitoneally or intravesicularly (kidneys). In the case of intravenous administration it is convenient if the volume of the composition administered is from twenty-five
- 10 milliliters to one liter. In the case of intratumoral administration it is convenient if the volume of composition administered is from one hundred microliters to ten milliliters per tumor mass. In the case of intraperitoneal administration it is convenient if the volume of composition administered is up to two liters. In the case of intravesicular administration it is convenient if the volume of composition
- 15 administered is up to seventy-five milliliters, preferably from fifty to sixty milliliters. Depending on the amount of pfus of virus and cells to be administered the concentration of the composition can be varied to achieve the desired volume. When the cancer is a solid tumor the composition can be administered by any of the routes given above, for example intravenously or intratumorally. When the
- 20 cancer is other than a solid tumor (e.g. leukemia) the composition is not administered intratumorally and instead can be administered by the other routes given above, for example intravenously.

The invention will be better understood by reference to the following examples which illustrate but do not limit the invention described herein. In the following examples the NDV used was a triple-plaque purified attenuated (moderately virulent) version of the MK107 strain of Newcastle Disease Virus, described more fully in international patent publication WO 00/62735, published October 26, 2000 (Pro-Virus, Inc.).

EXAMPLES

EXAMPLE 1: Binding of NDV to Human Blood Cells

5 Purpose: Investigate the binding of NDV to human blood cells in order to determine which cell types bind the virus.

Materials: Reference lot RL-004 NDV; Antibody Mab2F12 (3.5mg/ml) is raised to NDV HN protein; BD PharMingen Stain Buffer (PSB) containing 2% fetal bovine serum and 0.02% sodium azide, catalog #554656, lot M059394; Rockland goat anti-mouse polyclonal antibody – phycoerythrin conjugate, catalog #710-1832, lot 7367; Becton Dickinson Immunocytometry Systems 10X FACS Lysing Solution, Cat349202, lot#82026

15 Method: Human whole blood was collected in citrate tubes (3.2%, 0.105M, Becton Dickinson #366415). Approximately 4 ml from each of 2 tubes was pooled and kept at room temperature until use. Cells were counted using the trypan blue exclusion method and a hemocytometer. NDV lot number RL-004 (1.3E+10 PFU/ml) was used to infect the cells at MOIs (Multiplicity of Infection, 20 expressed as PFU/cell) of 0.2, 0.05 and 0.02 (along with a negative control of no added virus). After virus was added, tubes were incubated at 37°C for 30 minutes. Gentle mixing of the tubes to keep cells in suspension was performed at 3 intervals during the incubation period.

25 The samples were washed twice by adding 2ml of cold PSB, centrifuging for 5 minutes, 4°C, 2000 rpm, and aspirating the solution away from the cell pellet. The PSB was removed each time by aspiration. The volumes of each sample were adjusted to 1ml by adding cold PSB. The monoclonal antibody Mab2F12 was added to each sample by adding 20ul of a solution containing 9.1µg of the 30 antibody. The samples were incubated for 30 minutes on ice and washed twice again as previously described. The goat anti-mouse –PE reporter antibody was added to each sample by adding 1ml of a 12µg/ml solution of this antibody. The samples were again incubated for 30 minutes on ice and washed as described above. For analysis of the leukocyte fraction, 100µl of each sample was incubated

with 3ml of 1X FACS Lysing Solution for 6 minutes at room temperature. The samples were centrifuged and aspirated as before. The cell pellets were resuspended in 0.5ml of PSB. For erythrocyte analysis, 1.5 μ l of each sample was added to 2.0ml of PSB. Samples analysis was performed with a Becton Dickinson 5 FACSCalibur flow cytometer. Forward and side scatter parameters employed linear settings and FL2 detection of phycoerythrin employed logarithmic settings.

Results: The results of the experiment shown in Table 1 indicate that NDV binds preferentially to the leukocyte fraction of human whole blood. At an MOI 10 of 0.05 (to whole blood), 46% of the leukocytes are positive for NDV compared to 0% of the erythrocytes. At an MOI of 0.2 NDV is present on 89% of the leukocytes while bound to only 15% of the erythrocytes. Note that MOI's of 0.05 and 0.2 are approximately 5 and 200 to the leukocytes if the presence of the 15 erythrocytes is discounted. The small amount of NDV binding to erythrocytes at the higher MOI may reflect low affinity binding to sialic residues on proteins present on the surface of these cells.

Table 1: % Cells Positive for NDV Binding

MOI	Erythrocytes	Leukocytes
0.05	0	46
0.2	15	89

20 It is generally appreciated that Paramyxoviridae interact with erythrocytes and produce haemagglutination of the erythrocytes (see How, C. and Lee, L.T., "Virus-Erythrocyte Interactions"). Thus, it is commonly believed that the major cell type involved in the binding of these viruses, including NDV, are the erythrocytes. The binding of NDV to cells is thought to occur through the 25 interaction of the Neuraminidase activity of the viral HN protein to sialic acid residues attached to cell surface proteins. Human erythrocytes have a very high density of sialic acid residues attached to surface proteins for the purpose of keeping the cells in solution in the blood. As the ratio of erythrocytes to leukocytes in human blood is approximately 1000 to 1, it is especially surprising

that NDV binds to the leukocyte fraction instead of the vastly more numerous erythrocytes.

EXAMPLE 2: NDV Associates with Leukocytes in the Presence of NDV

5 Neutralizing Antibody

Introduction/Background: The purpose of this experiment was to assess the ability of NDV to bind to leukocytes in the presence or absence of NDV neutralizing antibody. Human clinical patient 521 received approximately 27 10 treatment courses of NDV therapy prior to having whole blood drawn for this experiment. Patient 521 displayed significant levels of NDV neutralizing antibodies as detected by plaque neutralization and micro-neutralization assays.

Methods: Human whole blood from a naïve donor and patient 521 were 15 collected in citrate tubes (3.2%, 0.105M, Becton Dickenson #366415). The tubes from each donor were kept at room temperature. Whole blood was divided into aliquots and spiked with NDV (lot number RL-005). NDV was spiked at MOIs (multiplicity of infection, expressed as PFU/cell) of 0.2, 0.02 and 0.002 (along with a negative control of no added virus). After virus was added, tubes were 20 incubated at room temperature for 30 minutes. Plasma and leukocytes were isolated from the spiked samples by gradient centrifugation using polymorphprep (Nycomed, Inc.). Plasma was carefully removed from the top of the gradient. Two Leukocyte bands (a polymorphonuclear cell band and a mononuclear cell band) were collected and placed in 0.5X DMEM. Cells were pelleted and 25 resuspended in full strength DMEM. Cells were washed several times to remove the separation media. Leukocytes in each aliquot were enumerated using a Coulter Counter. Known numbers of leukocytes or volumes of plasma were co-cultured or inoculated onto monolayers of HT1080 human fibrosarcoma cells (ATCC, CCL-121) in 25 cm² tissue culture flasks (Corning). HT1080 cells are 30 highly sensitive to cytolysis by NDV. Monolayers were evaluated qualitatively over several days for the presence of CPE (cytopathic effect). Flasks which exhibited CPE were considered positive.

Results: As shown in Table 2, for both the naïve donor and patient 521, at 300,000 leukocytes per flask for all three MOI spikes, both flasks tested were positive for infectivity by NDV. For the naïve donor, all flasks were positive at the 3000 cell level and all but the lowest MOI spike was positive at the 30 cell level. At the 3000 cell level for patient 521, 1 of 2 flasks were positive at the 0.02 MOI and 0 of 2 at the 0.002 MOI. At the 30 cell level for patient 521, 1 of 2 flasks were positive at the 0.2 MOI, all other flasks at this cell level were negative.

10 The plasma data show that in the naïve patient, virus could be recovered from the plasma at all MOIs tested (see Table 3). However, no infectious virus was recovered from patient 521 plasma which contained neutralizing antibody.

15 Discussion: The results show that the number of leukocytes associated with infectious virus was reduced in patient 521 compared to the naïve donor. However, virus was still able to bind to leukocytes in the presence of neutralizing antibody. This binding was shown to occur even at low MOI (0.002), which is similar to the MOI for patient dosing.

20 NDV elicits a humoral immune response which results in the production of neutralizing antibody. Binding of virus to leukocytes may allow the virus to be protected from the neutralizing antibody. This is an advantage over free virus, which is exposed to the neutralizing antibody and rendered non-infectious.

25 It can be concluded from these data that using leukocytes as a vehicle to deliver virus to tumors is an advantage over free circulating virus which would be rendered non-infectious by neutralizing antibody in patients that have generated an immune response (ie. Patients which have received multiple doses of NDV).

Table 2: Evaluation of Leukocytes for the Presence of Bound Infectious NDV

Naïve Donor

NDV Spike (MOI)	Number of Positive Cultures After Leukocytes are Placed in Co-Culture with a Monolayer of HT1080 Cells in a T25 Flask		
	300,000 Cells	3000 Cells	30 Cells
0.2	2*	2	2
0.02	2	2	2
0.002	2	2	0
No Spike (Ctl.)	0	0	0

5 Patient 521

NDV Spike (MOI)	Number of Positive Cultures After Leukocytes are Placed in Co-Culture with a Monolayer of HT1080 Cells in a T25 Flask		
	300,000 Cells	3000 Cells	30 Cells
0.2	2*	2	1
0.02	2	1	0
0.002	2	0	0
No Spike (Ctl.)	0	0	0

* Number of positive flasks per 2 flasks tested.

Table 3: Evaluation of Plasma for the Presence of Infectious NDV

Sample	Naïve Donor	Patient 521
0.2 MOI Spike	1	0
0.02 MOI Spike	1	0
0.002 MOI Spike	1	0
No Spike (Control)	0	0

N=1 flask

5 As NDV is not pathogenic in man it is a surprising result to find that NDV binds preferentially to the white blood cell component of human blood.

EXAMPLE 3: Preparation of Human Leukocyte / NDV Complex

10 Human Leukocytes (5×10^{8} cells) are prepared by leukaphoresis or by gradient centrifugation employing POLYMORPHPREP (Nycomed, Inc.) using the manufacturer's instructions. The cells are washed twice in sterile 1XPBS at room temperature and brought to a volume of 10ml in the same buffer. The cells are mixed with 1×10^{10} pfu of NDV (added aseptically) and allowed to sit for 30 minutes (with further brief mixings at 10 and 20 minutes). The cells are centrifuged for 5 minutes at 1500 rpm and the PBS removed. The cells are washed with 20ml of 1XPBS and centrifuged again. The cell pellet is diluted to 10ml for injection.

15 EXAMPLE 4: Treatment of Human Tumor Xenografts (<10mm and >5mm) in Athymic Mice with human Leukocyte/NDV Complex

20 Athymic mice are injected intradermally with 10 million human tumor cells. After tumors reached a size range of between 5 and 10mm, a single injection of 25 8×10^{6} cells of the Leukocyte/NDV complex described in Example 3 is given. The effect of LVC on tumor growth is examined for complete and partial regressions.

EXAMPLE 5: Systemic Treatment of Human Tumors with human Leukocyte/NDV Complex in Patients

Human leukocytes are obtained by leukapheresis from patients. The leukocyte/NDV complex (LVC) is prepared as described in Example 3. The complex ($5 \times 10^{+8}$ cells) is returned to the patient by intravenous injection.

5 Injections of LVC are given at three-day intervals for 21 days.

EXAMPLE 6: Systemic Treatment of Human Tumors with human Donor Leukocyte/NDV Complex in Patients

10 Human leukocytes are obtained by leukapheresis from naïve donors. The leukocyte/NDV complex (LVC) is prepared as described in Example 3. The complex ($5 \times 10^{+8}$ cells) is returned to the patient by intravenous injection. Injections of LVC are given at three-day intervals for 21 days.

15 EXAMPLE 7: Binding of NDV to Mouse Blood cells

Purpose: Investigate the binding of NDV to mouse blood cells in order to determine which cell types bind the virus.

20 **Materials:** Reference lot RL-004 NDV; Antibody Mab2F12 (3.5mg/ml) is raised to NDV HN protein; BD PharMingen Stain Buffer (PSB) containing 2% fetal bovine serum and 0.02% sodium azide, catalog #554656, lot M059394; Rockland goat anti-mouse polyclonal antibody – phycoerythrin conjugate, catalog #710-1832, lot 7367; Becton Dickinson Immunocytometry Systems 10X FACS Lysing 25 Solution, Cat349202, lot#82026.

Method: Mouse whole blood was collected in citrate tubes (3.2%, 0.105M, Becton Dickinson #366415). Cells were counted using the trypan blue exclusion method and a hemocytometer. NDV lot number RL-005 (4.2E+10 PFU/ml) was 30 used to infect the cells at MOIs (Multiplicity of Infection, expressed as PFU/cell) of 0.2, 1 and 3 (along with a negative control of no added virus). After virus was added, tubes were incubated at 37°C for 30 minutes. Gentle mixing of the tubes to keep cells in suspension was performed at 3 intervals during the incubation period.

The samples were washed twice by adding 2ml of cold PSB, centrifuging for 5 minutes, 4°C, 2000 rpm, and aspirating the solution away from the cell pellet. The PSB was removed each time by aspiration. The volumes of each sample were 5 adjusted to 1ml by adding cold PSB. The monoclonal antibody Mab2F12 was added to each sample by adding 20ul of a solution containing 9.1µg of the antibody. The samples were incubated for 30 minutes on ice and washed twice again as previously described. A goat anti-mouse -PE reporter antibody was added to each sample by adding 1ml of a 12µg/ml solution of this antibody. The 10 samples were again incubated for 30 minutes on ice and washed as described. For analysis of the leukocyte fraction, 100µl of each sample was incubated with 3ml of 1X FACS Lysing Solution for 6 minutes at room temperature. The samples were centrifuged as before. The cell pellets were re-suspended in 0.5ml of PSB. For erythrocyte analysis, 1.5µl of each sample was added to 2.0ml of PSB. 15 Samples analysis was performed with a Becton Dickinson FACSCalibur flow cytometer. Forward and side scatter parameters employed linear settings and FL2 detection of phycoerythrin employed logarithmic settings.

Results: The results of the experiment shown in Table 4 indicate that unlike 20 the binding of NDV to human blood cells where the virus preferentially binds to leukocytes (Example 1), NDV binds preferentially to the erythrocyte fraction of whole mouse blood and does not bind to the leukocytes.

Table 4: % Cells Positive for NDV Binding

MOI	Erythrocytes	Leukocytes
0.2	30	1
1	80	1
3	92	1

25

At an MOI of 0.2 where human leukocytes are mostly positive for the binding of NDV, mouse leukocytes are negative.

EXAMPLE 8: Binding of NDV to Rat Blood Cells

Purpose: Investigate the binding of NDV to mouse Rat blood cells in order to determine which cell types bind the virus.

5

Materials: Reference lot RL-004 NDV; Antibody Mab2F12 (3.5mg/ml) is raised to NDV HN protein; BD PharMingen Stain Buffer (PSB) containing 2% fetal bovine serum and 0.02% sodium azide, catalog #554656, lot M059394; Rockland goat anti-mouse polyclonal antibody – phycoerythrin conjugate, catalog #710-10 1832, lot 7367; Becton Dickinson Immunocytometry Systems 10X FACS Lysing Solution, Cat349202, lot#82026.

Method: Whole blood (1.8ml) was collected in citrate tubes (3.2%, 0.105M, Becton Dickinson #366415) from a Sprague Dawley rat and kept at room 15 temperature until use. Cells were counted using the trypan blue exclusion method and a hemocytometer. NDV lot number RL-005 (4.2E+10 PFU/ml) was used to infect the cells at MOIs (Multiplicity of Infection, expressed as PFU/cell) of 0.05,0.2,0.5, 1 and 3 (along with a negative control of no added virus). After virus was added, tubes were incubated at 37°C for 30 minutes. Gentle mixing of the 20 tubes to keep cells in suspension was performed at 3 intervals during the incubation period.

The samples were washed twice by adding 2ml of cold PSB, centrifuging for 5 minutes, 4°C, 2000 rpm, and aspirating the solution away from the cell pellet. 25 The PSB was removed each time by aspiration. The volumes of each sample were adjusted to 1ml by adding cold PSB. The monoclonal antibody Mab2F12 was added to each sample by adding 20ul of a solution containing 9.1µg of the antibody. The samples were incubated for 30 minutes on ice and washed twice again as previously described. A goat anti-mouse –PE reporter antibody was 30 added to each sample by adding 1ml of a 12µg/ml solution of this antibody. The samples were again incubated for 30 minutes on ice and washed as described. For analysis of the leukocyte fraction, 100µl of each sample was incubated with 3ml of 1X FACS Lysing Solution for 6 minutes at room temperature. The samples were centrifuged as before. The cell pellets were re-suspended in 0.5ml of PSB.

cytometer. Forward and side scatter parameters employed linear settings and FL2 detection of phycoerythrin employed logarithmic settings.

Results: The results of the experiment shown in Table 5 indicate that NDV binds to rat leukocytes at a low MOI (0.02 and 0.05) while it does not bind well to the erythrocytes at these MOI's. The pattern appears to be intermediate between the binding of the virus to human leukocytes to which it binds preferentially and to mouse leukocytes, to which it does not bind.

10

Table 5: % Cells Positive for NDV Binding

MOI	Erythrocytes	Leukocytes
0.02	3	7
0.05	12	21
0.2	30	29
1	63	58
3	90	66

EXAMPLE 9: Binding of NDV to human Platelets

15 Purpose: Investigate the binding of NDV to human platelets

Materials: Reference lot RL-004 NDV; Antibody Mab2F12 (3.5mg/ml) is raised to NDV HN protein; BD PharMingen Stain Buffer (PSB) containing 2% fetal bovine serum and 0.02% sodium azide, catalog #554656, lot M059394; Rockland 20 goat anti-mouse polyclonal antibody – phycoerythrin conjugate, catalog #710-1832, lot 7367; Becton Dickinson Immunocytometry Systems 10X FACS Lysing Solution, Cat349202, lot#82026.

25

Method:

Isolation of Platelets

Whole human blood was collected in citrate tubes (3.2% 0.105M Citrate, Becton Dickinson # 366415). Seven milliliters of whole blood were placed into a 15ml polypropylene centrifuge tube. The tube was centrifuged at 800 g for 5 minutes at room temperature. Approximately 1.5 ml of platelet-rich plasma (PRP) was collected from the top of the centrifuge tube. Based on published values for yield, the sample was determined to contain 8.0E+8 cells/ml. 100 μ l of PRP was 10 infected with NDV (RL-005) at MOIs of 0.1, 10 and 100 for 30 minutes at room temperature.

The samples were washed twice by adding 2ml of cold PSB, centrifuging for 5 minutes, 4°C, 2000 rpm, and aspirating the solution away from the cell pellet. 15 The PSB was removed each time by aspiration. The volumes of each sample were adjusted to 1ml by adding cold PSB. The monoclonal antibody Mab2F12 was added to each sample by adding 20 μ l of a solution containing 9.1 μ g of the antibody. The samples were incubated for 30 minutes on ice and washed twice again as previously described. A goat anti-mouse -PE reporter antibody was 20 added to each sample by adding 0.1ml of a 12 μ g/ml solution of this antibody. The samples were again incubated for 30 minutes on ice and washed as described. Sample analysis was performed with a Becton Dickinson FACSCalibur flow cytometer. Forward and side scatter parameters employed linear settings and FL2 detection of phycoerythrin employed logarithmic settings.

25

Results: The results of the experiment shown in Table 6 indicate that NDV binds to human platelets. The number of platelets that are positive for binding of NDV does not increase greatly in the MOI range tested although the mean fluorescence does, indicating that more NDV binds to the positive portion of the 30 platelets as the MOI increases.

Table 6: NDV Binding To Human Platelets

MOI	% Positive Platelets	Mean Fluorescence
0	0	10
1	67	258
10	81	616
100	73	1005

EXAMPLE 10: Binding Hierarchy of NDV to human Leukocytes.

5 Materials: Reference lot RL-004; Antibody Mab2F12 (3.5mg/ml) was raised to NDV HN protein; BD PharmMingen™ Stain Buffer (PSB) containing 2% fetal bovine serum and 0.02% sodium azide, catalog # 544656, lot M059394; Rockland goat anti-mouse polyclonal antibody-phycoerythrin conjugate, catalog #7100-1832, lot 7367; Becton Dickinson Immunocytometry Systems™ 10X FACS

10 Lysing Solution Cat. 349202, Lot#82026.

Method: Human whole blood was collected in citrate tubes (3.2%, 0.105M, Becton Dickinson™ #366415). Approximately 4ml from each of two tubes was pooled and kept at room temperature until use. Cells were counted using the 15 trypan blue exclusion method and a hemocytometer. NDV lot number RL-004 (1.3E+10 PFU/ml) was used to infect 100µl samples of whole blood at MOIs (Multiplicity of Infection, expressed as PFU/cell) of 0, 0.005, 0.01, 0.02, 0.05, 0.1, and 0.2 to the whole blood. After virus was added, samples were incubated at 37°C for 30 minutes.

20 The samples were washed twice by adding 2ml of cold PSB, centrifuging for 5 minutes, 4°C, 2000 rpm, and aspirating the solution away from the pellet. The volumes of each sample were adjusted to 100µl with PSB. Monoclonal antibody Mab2F12 was added to each sample by adding 2µl of a solution made in PSB 25 containing 1µg of the antibody. The samples were incubated for 30 minutes on ice and washed twice again as previously described. The goat anti-mouse - PE reporter antibody was added to each sample by adding 100µl of a 12µg/ml solution of this antibody diluted 2.4:1 in PSB. The samples were incubated for 30

minutes on ice and washed as described above. To prepare the samples for leukocyte cell analysis, each sample was incubated with 3ml of 1X FACS Lysing Solution for 6 minutes at room temperature, then centrifuged and aspirated as before. The cell pellets were re-suspended in 0.5ml of PSB. Sample analysis was 5 performed with a Becton Dickinson FACSCalibur™ flow cytometer.

Granulocyte, lymphocyte and monocyte populations were gated by comparing the forward scatter and side scatter parameters for each sample. This was used to determine the number of cells positive for binding the virus and the mean fluorescence value of each of these populations for each sample.

10

The results (Table 7) indicate that NDV binds preferentially to the three cell populations. The order of preference is: monocyte > granulocyte >> lymphocyte. Furthermore, as shown from the mean fluorescence data, the monocyte population binds substantially more NDV than does the granulocyte population, and binds 15 much more virus than does the lymphocyte cell population.

Table 7

MOI	% Positive Cells			Mean Fluorescence		
	Monocyte	Granulocyte	Lymphocyte	Monocyte	Granulocyte	Lymphocyte
0	2	2	2	13	19	7
0.005	80	68	19	65	20	9
0.01	92	97	39	134	35	11
0.02	99	100	54	219	66	16
0.05	98	100	72	314	113	22
0.10	99	100	84	448	154	31
0.20	100	100	96	692	251	69

20

CLAIMS

What is claimed is:

1. Use of a pharmaceutical composition to treat a human subject with cancer,
5 the pharmaceutical composition comprising
g: (a) human cells and a replication-competent oncolytic virus in suspension in a
physiologically acceptable solution, wherein the cells are leukocytes, the virus
binds specifically to the leukocytes, and the ratio of plaque forming units of the
virus to number of leukocytes in the composition is at least 1:100; or (b) human
10 cells infected with an oncolytic virus in suspension in a physiologically acceptable
solution, wherein the cells are leukocytes or platelets.
2. A method of treating a human subject with cancer, comprising
administering to the subject an amount of a pharmaceutical composition effective
15 to treat the subject, the pharmaceutical composition comprising human cells and a
replication-competent oncolytic virus in suspension in a physiologically
acceptable solution,
wherein
the cells are leukocytes;
20 the virus binds specifically to the leukocytes; and
the ratio of plaque-forming units of the virus to number of leukocytes in
the composition is at least 1:100,
thereby treating the subject.
- 25 3. The use or method of any one of claims 1-2, wherein the pharmaceutical
composition comprises the oncolytic virus suspended in whole blood.
4. The use or method of any one of claims 1-3, wherein the ratio of plaque-
forming units of the virus to number of leukocytes in the composition is at least
30 1:1.
5. The use or method of claim 4, wherein the ratio of plaque-
forming units of the virus to number of leukocytes in the composition is from
about 1:1 to about 200:1.

6. The use or method of claim 5, wherein the ratio is about 200:1.
7. A method of treating a human subject with cancer, comprising administering to the subject an amount of a pharmaceutical composition effective to treat the subject, the pharmaceutical composition comprising human cells infected with an oncolytic virus in suspension in a physiologically acceptable solution, wherein the cells are leukocytes or platelets, thereby treating the subject.
8. The use or method of any one of claims 1-7, wherein the cells are cells of the subject.
9. The use or method of any one of claims 1-7, wherein the cells are cells of a donor other than the subject.
10. The use or method of any one of claims 1-9, wherein the cells are cultured.
11. The use or method of claim 10, wherein the cultured cells comprise an immortalized cell line.
12. The use or method of claim 11, wherein the immortalized cell line is U-937 or KG-1.
13. The use or method of any one of claims 1-12, wherein the cells are leukocytes.
14. The use or method of claim 13, wherein the leukocytes are leukocytes isolated by leukopheresis.
15. The use or method of any one of claims 13-14, wherein the leukocytes are active.
16. The use or method of any one of claims 13-14, wherein the leukocytes are inactive.

17. The use or method of any one of claims 13-16, wherein the leukocytes are monocytes, neutrophils, or lymphocytes.
18. The use or method of claim 17, wherein the leukocytes are tumor-infiltrating lymphocytes.
19. The use or method of any one of claims 1-3 and 7-11, wherein the cells are platelets.
- 10 20. The use or method of any one of claims 1 and 7-19, wherein the pharmaceutical composition comprises whole blood containing leukocytes or platelets infected with the virus.
- 15 21. The use or method of any one of claims 1-20, wherein the virus is of low to moderate virulence.
22. The use or method of any one of claims 1-21, wherein the virus is a clonal virus.
- 20 23. The use or method of any one of claims 1-22, wherein the infected cells are at least one-tenth of one percent of the total number of leukocytes and platelets in the composition.
- 25 24. The use or method of claim 23, wherein the infected cells are at least thirty percent of the total number of leukocytes and platelets in the composition.
25. The use or method of any one of claims 1-24, wherein the virus is selected from the group consisting of a Newcastle Disease Virus, a Mumps Virus, a Measles Virus, a Vesicular Stomatitis Virus, a Para-influenza Virus, an Influenza Virus, an Adenovirus, a Herpes I Virus, a Vaccinia Virus, and a Reovirus.
26. The use or method of claim 25, wherein the virus is a Newcastle Disease Virus of moderate virulence.

27. The use or method of any one of claims 1-18 and 20-26, wherein the effective amount of the pharmaceutical composition that is administered is a daily dosage containing from 6×10^6 to 6×10^{10} leukocytes per square meter of patient surface area.

28. The use or method of claim 27, wherein the daily dosage contains about 6×10^7 leukocytes per square meter of patient surface area.

10 29. The use or method of any one of claims 1, 7-11, and 19-26, wherein the effective amount is a daily dosage containing from 10^9 to 10^{11} platelets per square meter of patient surface area.

15 30. The use or method of claim 29, wherein the daily dosage contains about 10^{11} platelets per square meter of patient surface area.

31. The use or method of any one of claims 27-30, wherein the daily dosage is administered in a single administration.

20 32. The use or method of any one of claims 27-31, wherein the daily dosage is administered at a frequency of from one to seven times in a one-week period.

33. The use or method of any one of claims 1-32, wherein the composition is administered intravenously.

25 34. The use or method of claim 33, wherein the volume of the composition administered is from twenty-five milliliters to one liter.

30 35. The use or method of any one of claims 1-32, wherein the composition is administered intratumorally.

36. The use or method of claim 35, wherein the volume of composition administered is from one hundred microliters to ten milliliters per tumor mass.

37. The use or method of any one of claims 1-36, wherein the cancer is a solid tumor and the composition is administered intravenously or intratumorally.

5 38. The use or method of any one of claims 1-36, wherein the cancer is other than a solid tumor and the composition is administered intravenously.

39. The use or method of claim 38, wherein the cancer is leukemia.

10

40. The use or method of any one of claims 1-32, wherein the composition is administered intraperitoneally.

15

41. The use or method of claim 40, wherein the volume of composition administered is up to two liters.

42. The use or method of any one of claims 1-32, wherein the composition is administered intravesicularly.

20

43. The use or method of claim 42, wherein the volume of composition administered is up to seventy-five milliliters.

44. The use or method of claim 43, wherein the volume of composition administered is from fifty to sixty milliliters.

25

45. The use or method of any one of claims 1, 3-15 and 17-44 wherein the virus is replication competent.

46. The invention substantially as described herein.

30